NIH PAR · NCI · U01
PAR-27-073: Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in cancer epidemiology cohort studies that address specific knowledge gaps in cancer etiology and survivorship. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and sharing of data and biospecimen resources as appropriate.
- NOFO number
- PAR-27-073
- Type
- PAR
- Activity code
- U01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- May 4, 2026
- Opens
- Sep 5, 2026
- Expires
- Jul 6, 2029
PAR-27-073 due dates
8 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 05, 2026 * | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 * | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 * | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 * | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
| February 05, 2028 * | March 05, 2028 * | Not Applicable | July 2028 | October 2028 | December 2028 |
| June 05, 2028 * | July 05, 2028 * | Not Applicable | November 2028 | January 2029 | April 2029 |
| October 05, 2028 * | November 05, 2028 * | Not Applicable | March 2029 | May 2029 | July 2029 |
| February 05, 2029 * | March 05, 2029 * | Not Applicable | July 2029 | October 2029 | December 2029 |
| June 05, 2029 * | July 05, 2029 * | Not Applicable | November 2029 | January 2030 | April 2030 |
What its predecessor PAR-25-275 funded
PAR-27-073 reissues PAR-25-275. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 2 projects and $2.3M in FY2022–FY2026.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$2.3M
Award dollars under PAR-25-275, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $2.3M |
Institutions with the most funding
- Mayo Clinic Rochester$1.3M · 1 project
- Weill Medical Coll of Cornell Univ$1.1M · 1 project
Funding institutes
- NCI$2.3M · 2
Activity codes funded
- U012 records
Most recent new awards
- AYA Cohort to Enhance Survivorship in NYC (ACES-NYC) (opens NIH RePORTER)
Weill Medical Coll of Cornell Univ · 1U01CA301481-01A1 · NCI · Notice Mar 24, 2026
$1.1MU01
- The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (opens NIH RePORTER)
Mayo Clinic Rochester · 1U01CA308978-01 · NCI · Notice Mar 9, 2026
$1.3MU01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-27-073. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
NIH lists no related notices for PAR-27-073 yet.
Award terms
- Application types allowed
- New Resubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-25-275.
Other open NOFOs for U01
- RFA-CA-27-019Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)NCI · next due Oct 19, 2026
- PAR-25-325Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)NCI · next due Feb 4, 2027
- PAR-28-056Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-248Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)NCI · next due Feb 10, 2027
- PAR-26-134The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)NCI · next due Jun 5, 2027
- PAR-24-325Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)NIBIB · next due Jan 27, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.